Figure 9.

sihBVR inhibits Akt1 activation and stimulates glucose uptake. A) sihBVR treatment inhibits Akt1 activation by insulin and IGF-1. Cells were transfected with siRNA against hBVR or with pcDNA-HA-hBVR, and treated with IGF-1 or insulin. Akt1 was immunoprecipitated from cell lysate and assayed for kinase activity with Aktide substrate. Expression levels of hBVR were verified by Western blot test, with GSK3β serving as loading control. B) sihBVR treatment stimulates glucose uptake. Cells were transfected with siRNA against hBVR or with pcDNA-HA-hBVR, and assayed for glucose uptake in presence or absence of insulin, as described in Materials and Methods.